NCT03123406View on ClinicalTrials.gov

Efficacy and Safety of Cinacalcet in Ca, P and iPTH Levels in Patients With Mild, Moderate and Severe SHPT

PHASE4CompletedINTERVENTIONAL

Enrollment

750

Participants

Timeline

Start Date

April 19, 2017

Primary Completion Date

April 20, 2019

Study Completion Date

September 6, 2019

Conditions

Hyperparathyroidism; Secondary, Renal

Interventions

DRUG

Cinacalcet HCl

Administer Cinacalcet HCL to all subjects from 1st to 32nd week. Subjects choose to buy and take Cinacalcet HCL in real-world period from 33rd to 52nd week.

Trial Locations (1)

210002

Nanjing Jinling Hospital, Nanjing

All Listed Sponsors

lead

Kyowa Kirin China Pharmaceutical Co., Ltd.

INDUSTRY

NCT03123406 - Efficacy and Safety of Cinacalcet in Ca, P and iPTH Levels in Patients With Mild, Moderate and Severe SHPT | Biotech Hunter | Biotech Hunter